September 21st 2024
During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, HER2 0 metastatic breast cancer and a PIK3CA mutation.
September 16th 2024
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances...
October 10, 2024
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Roundtable Discussion: Hamilton Compares Therapy Options and Sequencing for Recurrent TNBC
September 25th 2022During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
Read More
KEYNOTE-522 Trial of Pembrolizumab Does Not Negatively Affect HRQOL Outcomes in TNBC
September 12th 2022Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.
Read More
Trastuzumab Deruxtecan Preserves QOL in HER2-Low Breast Cancer
September 11th 2022Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Read More
Sacituzumab Govitecan Shows Strong ORR, PFS Benefit in HER2-Low/IHC0 Metastatic Breast Cancer
September 10th 2022The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.
Read More
Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
September 10th 2022While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Read More
Dalpiciclib Improves PFS in the First-Line for HR+/HER2– Advanced Breast Cancer
September 9th 2022The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
Adding Oleclumab to Durvalumab and Chemotherapy Does Not Reach Clinical Benefit in Advanced TNBC
September 9th 2022Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.
Read More
Sactiuzumab Govitecan Significantly Improves OS in Pretreated HR+/HER2- Metastatic Breast Cancer
September 9th 2022Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.
Read More
Abemaciclib Plus Aromatase Inhibitors Shows Improved OS in HR+/HER2- Breast Cancer
September 9th 2022Updated findings of the MONARCH 3 trial of abemaciclib added to a nonsteroidal aromatase inhibitor presented at ESMO 2022 revealed prolonged overall survival in hormone receptor-positive, HER2-negative breast cancer.
Read More
Sacituzumab Govitecan Improves PFS in HR+/HER2- Metastatic Breast Cancer
September 6th 2022Sacituzumab govitecan demonstrated promising progression-free survival efficacy in patients with HR+/HER2-low and IHC0 status metastatic breast cancer, showing its potential as a future treatment option.
Read More
Hormone Therapy Discontinuation Rates Differ From Those in Randomized Trials
August 29th 2022Hot flashes related to adjuvant hormone therapy were predictive of worse breast cancer outcomes, according to research on disease-free survival and treatment discontinuation in patients with and without hot flashes.
Read More
Roundtable Discussion: Reviewing Management Options for a Patient With TNBC
August 24th 2022During a Targeted Oncology case-based roundtable event, Alison K. Conlin, MD, discussed with participants their choice of first- and second-line therapy for a patient with triple-negative breast cancer.
Read More
Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies
August 15th 2022During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.
Read More
FDA Grants Priority Review to NDA for Elacestrant in ER+/HER2- Advanced or mBC
August 11th 2022Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.
Read More
As Backlog of Delayed Cancer Screenings are Addressed, Inequities in Care Persist
August 10th 2022In an interview with Targeted OncologyTM, Debra Patt, MD, PhD, MBA, FASCO, discusses the impact of delayed cancer screenings in potential patients and how the COVID-19 pandemic has increased existing inequities in cancer care.
Read More
CDK4/6 Inhibitors are Beneficial in HR+ MBC Harboring ESR1 Mutations and Fusions
July 29th 2022In an interview with Targeted Oncology, Jamie Brett and Seth Wander, MD, PhD, discussed recent findings regarding CDK4/6 for patients with hormone receptor-positive metastatic breast cancer with ESR1 alterations.
Read More